this study examined this issue by assessing the hemodynamic effects of a pharmacological dose of glucagon ( 1 mg , intravenously ) in patients with cirrhosis and portal hypertension ( n = 10 ) and in subjects without significant liver disease ( controls = n = 5 ) .
C0023890
cirrhosis
C0023895
liver disease